二期临床-话题@MedSci

#二期临床#

22篇内容 | 1602人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1940400, encodeId=5946194040026, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=BioNTech基于mRNA技术的癌症疫苗开启二期临床试验，新冠疫苗与药物市场格局恐生变, objectType=article, longId=218235, objectId=e8f2218235c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8f2218235c1, replyNumber=0, likeNumber=0, createdTime=2022-01-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8f2218235c1, moduleTitle=BioNTech基于mRNA技术的癌症疫苗开启二期临床试验，新冠疫苗与药物市场格局恐生变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8f2218235c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940399, encodeId=4a101940399d9, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=NEJM：礼来Aβ抗体二期临床结果公布：达到主要终点，错失次要终点, objectType=article, longId=208386, objectId=c04f20838658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c04f20838658, replyNumber=0, likeNumber=86, createdTime=2021-04-30, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c04f20838658, moduleTitle=NEJM：礼来Aβ抗体二期临床结果公布：达到主要终点，错失次要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c04f20838658)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940398, encodeId=d5fc194039896, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=全球新冠肺炎疫苗启动二期临床科研攻关“中国方案”加速, objectType=article, longId=192350, objectId=fd1519235049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd1519235049, replyNumber=0, likeNumber=61, createdTime=2021-03-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd1519235049, moduleTitle=全球新冠肺炎疫苗启动二期临床科研攻关“中国方案”加速, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd1519235049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940397, encodeId=dfcb194039eb4, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=盟科医药新型抗生素Contezolid Acefosamil美国二期临床试验顺利完成首例患者入组, objectType=article, longId=154428, objectId=c05f154428fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c05f154428fa, replyNumber=0, likeNumber=72, createdTime=2019-10-16, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c05f154428fa, moduleTitle=盟科医药新型抗生素Contezolid Acefosamil美国二期临床试验顺利完成首例患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c05f154428fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940396, encodeId=898719403967b, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=Viking非酒精性脂肪性肝炎候选药VK2809二期临床试验成功, objectType=article, longId=149201, objectId=412214920109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=412214920109, replyNumber=0, likeNumber=81, createdTime=2019-02-09, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=412214920109, moduleTitle=Viking非酒精性脂肪性肝炎候选药VK2809二期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=412214920109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940395, encodeId=efa219403958e, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果, objectType=article, longId=120735, objectId=9988120e352a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9988120e352a, replyNumber=0, likeNumber=84, createdTime=2018-10-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9988120e352a, moduleTitle=ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9988120e352a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940393, encodeId=5498194039358, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=美国寨卡疫苗在多国开始二期临床试验, objectType=article, longId=94409, objectId=75bc9440985, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75bc9440985, replyNumber=0, likeNumber=0, createdTime=2017-06-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75bc9440985, moduleTitle=美国寨卡疫苗在多国开始二期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75bc9440985)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验, objectType=article, longId=103156, objectId=d8d010315642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d010315642, replyNumber=0, likeNumber=82, createdTime=2018-05-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d010315642, moduleTitle=Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8d010315642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940392, encodeId=e272194039242, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=全球大复方中药获批在美国进行二期临床研究, objectType=article, longId=61185, objectId=890c611854e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=890c611854e, replyNumber=0, likeNumber=62, createdTime=2016-07-31, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=890c611854e, moduleTitle=全球大复方中药获批在美国进行二期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=890c611854e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940386, encodeId=74cf19403867e, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=靶向药物ENMD-2076治疗三阴性乳腺癌国际多中心二期临床试验启动, objectType=article, longId=48711, objectId=d3ba48e1129, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3ba48e1129, replyNumber=0, likeNumber=83, createdTime=2016-03-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3ba48e1129, moduleTitle=靶向药物ENMD-2076治疗三阴性乳腺癌国际多中心二期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3ba48e1129)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940385, encodeId=625d194038514, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=歌礼丙肝新药ASC08二期临床试验数据发布, objectType=article, longId=48323, objectId=c6684832389, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6684832389, replyNumber=0, likeNumber=65, createdTime=2016-01-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6684832389, moduleTitle=歌礼丙肝新药ASC08二期临床试验数据发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6684832389)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940387, encodeId=0439194038e84, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=NEJM：Mongersen治疗克罗恩病二期临床试验, objectType=article, longId=48856, objectId=40ca488567e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ca488567e, replyNumber=0, likeNumber=75, createdTime=2015-04-01, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ca488567e, moduleTitle=NEJM：Mongersen治疗克罗恩病二期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ca488567e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940383, encodeId=311f1940383e6, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=中国艾滋病疫苗已完成二期临床研究, objectType=article, longId=43652, objectId=e54c4365204, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e54c4365204, replyNumber=0, likeNumber=80, createdTime=2015-07-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e54c4365204, moduleTitle=中国艾滋病疫苗已完成二期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e54c4365204)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940391, encodeId=64d7194039174, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=JCO：合理的临床试验——评价先验概率对二期临床试验的影响, objectType=article, longId=54922, objectId=792a5492298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=792a5492298, replyNumber=0, likeNumber=51, createdTime=2016-03-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=792a5492298, moduleTitle=JCO：合理的临床试验——评价先验概率对二期临床试验的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=792a5492298)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940389, encodeId=2f3e194038978, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=安全隐患困扰 SMA新药RG7800二期临床试验被暂停, objectType=article, longId=50382, objectId=045d5038209, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=045d5038209, replyNumber=0, likeNumber=77, createdTime=2016-01-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=045d5038209, moduleTitle=安全隐患困扰 SMA新药RG7800二期临床试验被暂停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=045d5038209)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=Ardelyx重磅药物tenapanor（NHE3受体抑制剂）二期临床试验失利, objectType=article, longId=50383, objectId=d6d7503835f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6d7503835f, replyNumber=0, likeNumber=76, createdTime=2016-01-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6d7503835f, moduleTitle=Ardelyx重磅药物tenapanor（NHE3受体抑制剂）二期临床试验失利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6d7503835f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940388, encodeId=fd59194038873, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=基因治疗再遇滑铁卢，Celladon心衰药物二期临床失败, objectType=article, longId=49996, objectId=fe9949996ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe9949996ad, replyNumber=0, likeNumber=64, createdTime=2015-07-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe9949996ad, moduleTitle=基因治疗再遇滑铁卢，Celladon心衰药物二期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe9949996ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940384, encodeId=107c19403840e, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=Lancet Oncol：二期临床发现帕尼单抗不适用于晚期头颈部鳞癌, objectType=article, longId=46053, objectId=5ebb46053a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ebb46053a6, replyNumber=0, likeNumber=79, createdTime=2015-01-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ebb46053a6, moduleTitle=Lancet Oncol：二期临床发现帕尼单抗不适用于晚期头颈部鳞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ebb46053a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940382, encodeId=b3461940382b0, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=Achillion丙肝药物ACH-3102二期临床数据良好有望挑战Sovaldi, objectType=article, longId=39211, objectId=2b2b39211da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b2b39211da, replyNumber=0, likeNumber=72, createdTime=2014-12-31, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b2b39211da, moduleTitle=Achillion丙肝药物ACH-3102二期临床数据良好有望挑战Sovaldi, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b2b39211da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940381, encodeId=eae819403813b, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, objectTitle=La Jolla治疗慢性肾病药物二期临床结果良好, objectType=article, longId=31833, objectId=301e31833ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=301e31833ed, replyNumber=0, likeNumber=77, createdTime=2015-01-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=301e31833ed, moduleTitle=La Jolla治疗慢性肾病药物二期临床结果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=301e31833ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

二期临床

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

BioNTech基于mRNA技术的癌症疫苗开启二期临床试验，新冠疫苗与药物市场格局恐生变

2022-01-15

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

NEJM：礼来Aβ抗体二期临床结果公布：达到主要终点，错失次要终点

2021-04-30

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

全球新冠肺炎疫苗启动二期临床科研攻关“中国方案”加速

2021-03-03

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

盟科医药新型抗生素Contezolid Acefosamil美国二期临床试验顺利完成首例患者入组

2019-10-16

智者为医08 (审核中...)

前往app查看评论内容

#二期临床#

Viking非酒精性脂肪性肝炎候选药VK2809二期临床试验成功

2019-02-09

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果

2018-10-27

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

美国寨卡疫苗在多国开始二期临床试验

2017-06-23

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验

2018-05-05

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

全球大复方中药获批在美国进行二期临床研究

2016-07-31

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

靶向药物ENMD-2076治疗三阴性乳腺癌国际多中心二期临床试验启动

2016-03-05

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

歌礼丙肝新药ASC08二期临床试验数据发布

2016-01-09

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

NEJM：Mongersen治疗克罗恩病二期临床试验

2015-04-01

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

中国艾滋病疫苗已完成二期临床研究

2015-07-05

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

JCO：合理的临床试验——评价先验概率对二期临床试验的影响

2016-03-19

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

安全隐患困扰 SMA新药RG7800二期临床试验被暂停

2016-01-10

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

Ardelyx重磅药物tenapanor（NHE3受体抑制剂）二期临床试验失利

2016-01-02

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

基因治疗再遇滑铁卢，Celladon心衰药物二期临床失败

2015-07-06

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

Lancet Oncol：二期临床发现帕尼单抗不适用于晚期头颈部鳞癌

2015-01-28

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

Achillion丙肝药物ACH-3102二期临床数据良好有望挑战Sovaldi

2014-12-31

jklm09 (审核中...)

前往app查看评论内容

#二期临床#

La Jolla治疗慢性肾病药物二期临床结果良好

2015-01-07

科室
- - 订阅+
  - 更多科室
工具
服务